GSK stops development of 30 pipeline prospects, mulls sale of rare disease unit by Nick Paul Taylor Wednesday, July 26, 2017 The cull of will see GSK focus 80% of its R&D budget on the top candidates in four therapeutic areas and potentially exit the rare disease space.
